Understanding how T cells respond to specific cancer mutations.
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.
This study is looking at how a special type of immune cell called T cells can better fight cancer cells with certain changes in a gene called PIK3CA, with the goal of creating new treatments that could help patients whose cancers don’t respond well to current therapies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11065538 on NIH RePORTER |
What this research studies
This research investigates how T cells, a type of immune cell, can effectively target and respond to cancer cells that have specific mutations in the PIK3CA gene. By analyzing the unique neoantigens produced by these mutations, the study aims to develop new immunotherapy strategies that could enhance the effectiveness of treatments for patients with cancers that are typically resistant to current therapies. The approach involves detailed immune monitoring and bioinformatics to identify and characterize these neoantigens, potentially leading to personalized treatment options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that have mutations in the PIK3CA gene and who have not responded well to conventional treatments.
Not a fit: Patients with cancers that do not involve PIK3CA mutations or those who have already responded well to existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with cancers driven by PIK3CA mutations.
How similar studies have performed: Previous research has shown promising results in utilizing neoantigens for immunotherapy, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Klebanoff, Christopher Austin — Sloan-Kettering Inst Can Research
- Study coordinator: Klebanoff, Christopher Austin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.